Presentation is loading. Please wait.

Presentation is loading. Please wait.

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer 

Published byJohn Quinn Modified over 5 years ago

Similar presentations

Presentation on theme: "Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer "— Presentation transcript:

1 Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer  Shoichi Kuyama, MD, Katsuyuki Hotta, MD, PhD, Masahiro Tabata, MD, PhD, Yoshihiko Segawa, MD, PhD, Yoshiro Fujiwara, MD, Nagio Takigawa, MD, PhD, Katsuyuki Kiura, MD, PhD, Hiroshi Ueoka, MD, PhD, Kenji Eguchi, MD, PhD, Mitsune Tanimoto, MD, PhD  Journal of Thoracic Oncology  Volume 3, Issue 5, Pages (May 2008) DOI: /JTO.0b013e31816e2ea3 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Association between the HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assay results. The FISH results were expressed as the ratio of HER2 to chromosome 17 copy number in each patient. The IHC results were divided into two categories according to the HercepTest kit scoring guidelines: negative (score 0 to 1+) and positive (score 2+ to 3+). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31816e2ea3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Survival curves stratified by HER2-fluorescence in situ hybridization (FISH) results. Bold and nonbold lines represent patients with positive and negative FISH results, respectively. A, Overall survival Curves (5-year overall survival rate and median survival time of patients with HER2-FISH positive and negative tumors of 22.7% and 40.9%, respectively, and 15.5 months and 29.7 months, respectively; log-rank test; p = ). B, Progression-Free survival Curves (median progression-free survival times of 10.0 months and 14.1 month in those with the positive and negative HER2-FISH results, respectively, log-rank test; p = ). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31816e2ea3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Survival curves stratified by HER2-FISH results. Bold and nonbold lines represent patients with HER2-protein positive (score 2+ to 3+) and negative (score 0 to 1+) tumors, respectively. A, Overall survival Curves (5-year overall survival rate and median survival time of patients with HER2-FISH positive and negative tumors of 39.1% and 31.1%, respectively, and 28.3 months and 23.6 months, respectively; log-rank test; p = ). B, Progression-Free survival Curves (median progression-free survival times of 14.1 month and 10.6 months in those with the positive and negative HER2-FISH results, respectively, log-rank test; p = ). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e31816e2ea3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer "

Similar presentations

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.

Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.
Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer  Kadoaki Ohashi, MD, Kastuyuki Kiura, MD, PhD,

Radiation Necrosis Mimicking Progressive Brain Metastasis in a Patient with Non-small Cell Lung Cancer  Kadoaki Ohashi, MD, Kastuyuki Kiura, MD, PhD,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,

Clinicopathological and Survival Analysis of Japanese Patients with Resected Non- Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1,
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer  Katsuyuki Kiura,
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Similar presentations

Ads by Google